On Monday, October 12th, Andrew Craig Miller sold 5,000 shares of Karuna Therapeutics stock. salesforce.com (NYSE:CRM) Earns “Buy” Rating from The Goldman Sachs Group » NEXT. Karuna Therapeutics CEO Dr. Steve Paul told CNBC on Friday that the biotech firm is hopeful its new therapy for schizophrenia will prove effective for patients in … Finally, ValuEngine upgraded Karuna Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 20th. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. On December 22, 2020, the board of directors (the "Board") of Karuna Therapeutics, Inc. (the "Company") appointed Denice Torres as a member of the Company's Board, effective immediately. This saw it met the primary endpoint of the study. Includes articles, videos and real-time news from StockTwits. Karuna Therapeutics believes it can preferentially target and stimulate muscarinic receptors in the central nervous system, and leave those in the peripheral tissues unaffected. BlackRock Inc. ]]> Mr. Ignelzi has played a key role in seven IPOs, and currently serves as the chief financial officer of Karuna Therapeutics. Get Karuna Therapeutics Inc (KRTX:NASDAQ) real-time stock quotes, news and financial information from CNBC. ET on Zacks.com. 20, 2020 at 8:48 a.m. Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Karuna Therapeutics is bringing together a community of scientists, clinicians, and leaders with deep expertise in neuroscience and drug development. Troy A. Ignelzi joined Karuna Therapeutics as Chief Financial Officer in March 2019, bringing more than 25 years of experience supporting companies in finance, business development and operations. Why Karuna Therapeutics Stock Is Skyrocketing Today. ET on Zacks.com. Share Price & News. Karuna Therapeutics (NASDAQ:KRTX) COO Andrew Craig Miller sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, December 10th. There are no upcoming events available at this time. BlackRock Inc. owned 4.84% of Karuna […] //-->